How I Treat Hematologic Malignancy:
A Practical Guide for Oncologists
prIME Oncology Integrated Session at the
22nd International Congress on Anti-Cancer Treatment |
Date and Location | 2 February 2011
09.00 – 17.30
Room 2
Palais des Congrès
Paris, France |
Invited Faculty | Chair and Moderator
James Armitage, MD
University of Nebraska
Omaha, Nebraska, United States
Faculty
Andreas Engert, MD
University Hospital of Cologne
Cologne, Germany
Aristoteles Giagounidis, MD, PhD
St Johannes Hospital
Duisburg, Germany
Christian Gisselbrecht, MD
St Louis Hospital
Paris, France
Emilio Montserrat, MD
Postgraduate School of Hematology
Hospital Clinic
Barcelona, Spain
Enrique Ocio, MD, PhD
University of Salamanca
Salamanca, Spain
Giuseppe Saglio, MD
University of Turin
Turin, Italy |
 Agenda |
| 09.00 |
|
Welcome, introduction, and demographics
James Armitage, MD
|
| 09.10 |
|
Myelodysplastic syndromes
Aristoteles Giagounidis, MD, PhD
|
| 09.50 |
|
Q&A
Faculty Panel
|
| 10.00 |
|
Chronic myelogenous leukemia
Giuseppe Saglio, MD
|
| 10.40 |
|
Q&A
Faculty Panel |
| 10.50 |
|
Break |
| 11.10 |
|
Chronic lymphocytic leukemia
Emilio Monserrat, MD
|
| 11.50 |
|
Q&A
Faculty Panel |
| 12.00 |
|
Lunch |
| 14.00 |
|
Relapsed/refractory multiple myeloma
Enrique Ocio, MD, PhD
|
| 14.40 |
|
Q&A
Faculty Panel |
| 14.50 |
|
Diffuse large B-cell lymphoma
Christian Gisselbrecht, MD
|
| 15.30 |
|
Q&A
Faculty Panel |
| 15.40 |
|
Break |
| 16.00 |
|
Relapsed Hodgkin lymphoma
Andreas Engert, MD
|
| 16.40 |
|
Q&A
Faculty Panel |
| 16.50 |
|
Follicular lymphoma
James Armitage, MD
|
| 17.30 |
|
Q&A and concluding remarks
James Armitage, MD
|
|
Target Audience | This educational activity is specifically designed for oncologists, hematologists, and other healthcare professionals involved and/or interested in the management of patients with hematologic malignancies. |
Educational Objectives | Upon completion of this educational activity, participants should be able to:
- Describe the latest management approaches for hematologic disorders, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes
- Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologists and identify appropriate management options based on emerging data
- Compare and contrast the current standard of care with emerging therapies for the management of patients with hematologic malignancies and associated disorders
- Summarize emerging data in the management of multiple hematologic malignancies and integrate new finding into clinical practice
|
|
|
|
Organizer | This meeting is a prIME Oncology activity.
|
Support | This educational activity is supported by Cephalon Oncology and Millennium: The Takeda Oncology Company.
|
|
